Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibitors of cytochrome P450 (CYP) 1B1
Raphaël Dutour, Donald Poirier
European Journal of Medicinal Chemistry (2017) Vol. 135, pp. 296-306
Closed Access | Times Cited: 55

Showing 26-50 of 55 citing articles:

Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
Shizhen Ding, Guotao Lu, Biying Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 13
Structure-Based Design and Synthesis of New Estrane–Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors
Raphaël Dutour, Francisco Cortés‐Benítez, Jenny Roy, et al.
ACS Medicinal Chemistry Letters (2017) Vol. 8, Iss. 11, pp. 1159-1164
Open Access | Times Cited: 21
Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone
Makoto Kubo, Keiko Yamamoto, Toshimasa Itoh
Bioorganic & Medicinal Chemistry (2018) Vol. 27, Iss. 2, pp. 285-304
Closed Access | Times Cited: 21
Redox reactions of heme proteins with flavonoids
Lidia Gȩbicka
Journal of Inorganic Biochemistry (2020) Vol. 208, pp. 111095-111095
Closed Access | Times Cited: 18
The Activation of Procarcinogens by CYP1A1/1B1 and Related Chemo-Preventive Agents: A Review
Yubei Li, Jiahua Cui, Jinping Jia
Current Cancer Drug Targets (2020) Vol. 21, Iss. 1, pp. 21-54
Closed Access | Times Cited: 18
Design, Synthesis, and Biological Evaluation of Cytochrome P450 1B1 Targeted Molecular Imaging Probes for Colorectal Tumor Detection
Qingqing Meng, Zengtao Wang, Jiahua Cui, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 23, pp. 10901-10909
Closed Access | Times Cited: 19
The smoking estrogens – a potential synergy between estradiol and benzo(a)pyrene
Bartosz Słowikowski, Maurycy Jankowski, Paweł P. Jagodzińśki
Biomedicine & Pharmacotherapy (2021) Vol. 139, pp. 111658-111658
Open Access | Times Cited: 14
3,5,2′,4′-Tetramethoxystilbene, a fully methylated resveratrol analog, prevents platelet aggregation and thrombus formation by targeting the protease-activated receptor 4 pathway
Yi-Chun Chiang, Yu‐Shan Wu, Yafei Kang, et al.
Chemico-Biological Interactions (2022) Vol. 357, pp. 109889-109889
Closed Access | Times Cited: 10
Discovery of 4’-trifluoromethylchalcones as novel, potent and selective hCYP1B1 inhibitors without concomitant AhR activation
Yue Wu, Jin-Hui Shi, Guanghao Zhu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115552-115552
Closed Access | Times Cited: 5
WY-14643 Regulates CYP1B1 Expression through Peroxisome Proliferator-Activated Receptor α-Mediated Signaling in Human Breast Cancer Cells
Yong Pil Hwang, Seong Su Won, Sun Woo Jin, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 23, pp. 5928-5928
Open Access | Times Cited: 16
Design of Cytochrome P450 1B1 Inhibitors via a Scaffold-Hopping Approach
Austin C. Hachey, Alexander D. Fenton, David K. Heidary, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 398-412
Closed Access | Times Cited: 9
Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs
Laxmi Manthalkar, M. Ajazuddin, Sankha Bhattacharya
Discover Oncology (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1
Mohd Usman Mohd Siddique, Tabassum Khair Barbhuiya, Barij Nayan Sinha, et al.
European Journal of Medicinal Chemistry (2018) Vol. 163, pp. 28-36
Closed Access | Times Cited: 11
Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs
Ying Wang, Baichun Hu, Yupeng Zhang, et al.
Physical Chemistry Chemical Physics (2021) Vol. 23, Iss. 36, pp. 20230-20246
Closed Access | Times Cited: 8
Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity
Joo-Youn Lee, Hyun-kyung Cho, Sundarapandian Thangapandian, et al.
ACS Medicinal Chemistry Letters (2018) Vol. 9, Iss. 12, pp. 1247-1252
Open Access | Times Cited: 7
Cytochrome P450 in GtoPdb v.2023.1
Kathryn Burns, Nuala A. Helsby
IUPHAR/BPS Guide to Pharmacology CITE (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 2
Functional characterization of CYP1 enzymes: Complex formation, membrane localization and function
J. Patrick Connick, James R. Reed, George F. Cawley, et al.
Journal of Inorganic Biochemistry (2023) Vol. 247, pp. 112325-112325
Open Access | Times Cited: 2
Design, Synthesis, and Evaluation of 18F-Labeling CYP1B1 PET Tracer Based on 2-Phenylquinazolin
Jiajing Cai, Lan Yi, Xia Zhu, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 96, pp. 129533-129533
Closed Access | Times Cited: 2
The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells
Ketan C. Ruparelia, Sabahat Lodhi, Dyan N. Ankrett, et al.
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 11, pp. 1403-1406
Open Access | Times Cited: 6
3D-QSAR assisted identification of selective CYP1B1 inhibitors: an effective bioisosteric replacement/molecular docking/electrostatic complementarity analysis
Baddipadige Raju, Bharti Sapra, Om Silakari
Molecular Diversity (2022) Vol. 27, Iss. 6, pp. 2673-2693
Closed Access | Times Cited: 4
The literature of heterocyclic chemistry, part XVII, 2017
Л. И. Беленький, Yu. B. Evdokimenkova
Advances in heterocyclic chemistry (2019), pp. 337-418
Closed Access | Times Cited: 5
Efficient synthesis and molecular docking of new organoselenium and organosulphur compounds as dual inhibitors for the therapy of Alzheimer's disease as well as Diabetes Mellitus
Naglaa F. El‐Sayed, Nagwa M. Abdelazeem, Amal G. Hussien, et al.
Journal of Molecular Structure (2024), pp. 140606-140606
Closed Access
The crucial involvement of gamma-Mangostin and CYP1B1 in the mechanism underlying the toxicity caused by cigarette smoke extract: In silico and in vitro insights
Hao Lin, Zijian Li, Tao Zeng, et al.
Toxicology (2024) Vol. 510, pp. 154016-154016
Closed Access
Structure-based design and development of halogenated-naphthalimides as potent hCYP1B1 inhibitors for overcoming paclitaxel resistance
Yuan Xiong, Qin Li, Bei Zhao, et al.
Chinese Chemical Letters (2024), pp. 110812-110812
Closed Access
In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: An integrated in vitro and ONIOM study
Himani Sharma, Baddipadige Raju, Gera Narendra, et al.
Journal of Molecular Graphics and Modelling (2022) Vol. 119, pp. 108390-108390
Closed Access | Times Cited: 3

Scroll to top